A next generation CAR-T platform that provides physiological T cell signaling.
A next generation NK-CAR platform
Bispecific and multi-specific SIR-T and NK-CAR platforms
Universal SIR and NK-CAR platforms
Angeles platforms are fully compatible with allogeneic use
Use of Dasatinib to control CRS and other complications associated with cell therapies
A novel platform for providing selective NF-kappa B co-stimulus to CAR-T, TCR-T and other cell therapy products
A novel luciferase based assay to measure expression and affinity of cell therapy products
Angeles Therapeutics
preet.chaudhary@angelestherapeutics.com
Copyright © 2021 Angeles Therapeutics, Inc - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.